Pub Date : 2026-01-17DOI: 10.1016/j.sleepx.2026.100174
Emmanuel Eroumé A Egom , Bernadette Sandrine Lema , Elijah-Bill Christopher Nguem Nguem
Objective
To evaluate self-reported autonomic-like symptoms following sexual dreams in the SLEEP Study and characterize their perceived physiological patterns.
Methods
In a cross-sectional online study, 301 female-identifying adults reported physical and emotional sensations experienced immediately after sexual dreams. We summarized symptom prevalence using descriptive statistics.
Results
Increased heart rate (57.4 %) and sweating (35.0 %) were most frequently reported, followed by anxiety (33.9 %) and muscle tension (23.0 %). A minority (20.8 %) reported no symptoms, indicating variability in perceived arousal or recall. Symptom patterns reflected common co-occurrence of self-reported cardiovascular-like and affective experiences.
Discussion
These findings suggest that sexual dreams are often accompanied by self-reported autonomic-like experiences, although these reports do not represent objective physiological measurements. This brief report isolates the symptom dimension of the SLEEP Study dataset—a component not analyzed in our prior Sleep Research publication—and highlights the potential value of self-reported responses for studying REM-linked emotional arousal.
{"title":"Physiology of the subconscious: Autonomic activation during sexual dreaming","authors":"Emmanuel Eroumé A Egom , Bernadette Sandrine Lema , Elijah-Bill Christopher Nguem Nguem","doi":"10.1016/j.sleepx.2026.100174","DOIUrl":"10.1016/j.sleepx.2026.100174","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate self-reported autonomic-like symptoms following sexual dreams in the SLEEP Study and characterize their perceived physiological patterns.</div></div><div><h3>Methods</h3><div>In a cross-sectional online study, 301 female-identifying adults reported physical and emotional sensations experienced immediately after sexual dreams. We summarized symptom prevalence using descriptive statistics.</div></div><div><h3>Results</h3><div>Increased heart rate (57.4 %) and sweating (35.0 %) were most frequently reported, followed by anxiety (33.9 %) and muscle tension (23.0 %). A minority (20.8 %) reported no symptoms, indicating variability in perceived arousal or recall. Symptom patterns reflected common co-occurrence of self-reported cardiovascular-like and affective experiences.</div></div><div><h3>Discussion</h3><div>These findings suggest that sexual dreams are often accompanied by self-reported autonomic-like experiences, although these reports do not represent objective physiological measurements. This brief report isolates the symptom dimension of the SLEEP Study dataset—a component not analyzed in our prior <em>Sleep Research</em> publication—and highlights the potential value of self-reported responses for studying REM-linked emotional arousal.</div></div>","PeriodicalId":37065,"journal":{"name":"Sleep Medicine: X","volume":"11 ","pages":"Article 100174"},"PeriodicalIF":0.0,"publicationDate":"2026-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146037873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This study compared the efficacy and safety of integrative and conventional therapies for chronic insomnia.
Objective
To evaluate the effects of the Suk-Sai-Yat traditional Thai herbal remedy, Cannabis sativa oil (Deja formula) and lorazepam on sleep quality and quality of life in patients with chronic insomnia.
Methods
In a randomized controlled parallel-group trial, 60 adults with chronic insomnia received Suk-Sai-Yat, Cannabis sativa oil, or lorazepam for four weeks. Sleep quality was assessed using the Pittsburgh leep Quality Index (PSQI) and quality of life was evaluated using EQ-5D-5L and EQ-VAS. Safety was monitored throughout the study.
Results
After four weeks, PSQI scores significantly improved in all groups: Suk-Sai-Yat (12.3–6.6), Cannabis sativa oil (13.6–3.68) and lorazepam (14.4–5.8) (all p < 0.001), with no significant differences between groups. Quality-of-life scores improved significantly in the integrative therapy groups. Only mild adverse events were reported.
Conclusion
Suk-Sai-Yat and Cannabis sativa oil demonstrated comparable efficacy to lorazepam with favorable safety profiles, supporting their role as integrative, non-benzodiazepine options for chronic insomnia management.
{"title":"Integrative therapies for chronic insomnia: A randomized controlled trial of a traditional Thai Herbal Remedy and Cannabis sativa oil","authors":"Naruwat Pakdee, Nitcha Sribunrieng, Ronnachai Poowanna","doi":"10.1016/j.sleepx.2026.100173","DOIUrl":"10.1016/j.sleepx.2026.100173","url":null,"abstract":"<div><h3>Background</h3><div>This study compared the efficacy and safety of integrative and conventional therapies for chronic insomnia.</div></div><div><h3>Objective</h3><div>To evaluate the effects of the Suk-Sai-Yat traditional Thai herbal remedy, <em>Cannabis sativa</em> oil (Deja formula) and lorazepam on sleep quality and quality of life in patients with chronic insomnia.</div></div><div><h3>Methods</h3><div>In a randomized controlled parallel-group trial, 60 adults with chronic insomnia received Suk-Sai-Yat, <em>Cannabis sativa</em> oil, or lorazepam for four weeks. Sleep quality was assessed using the Pittsburgh leep Quality Index (PSQI) and quality of life was evaluated using EQ-5D-5L and EQ-VAS. Safety was monitored throughout the study.</div></div><div><h3>Results</h3><div>After four weeks, PSQI scores significantly improved in all groups: Suk-Sai-Yat (12.3–6.6), <em>Cannabis sativa</em> oil (13.6–3.68) and lorazepam (14.4–5.8) (all p < 0.001), with no significant differences between groups. Quality-of-life scores improved significantly in the integrative therapy groups. Only mild adverse events were reported.</div></div><div><h3>Conclusion</h3><div>Suk-Sai-Yat and <em>Cannabis sativa</em> oil demonstrated comparable efficacy to lorazepam with favorable safety profiles, supporting their role as integrative, non-benzodiazepine options for chronic insomnia management.</div></div>","PeriodicalId":37065,"journal":{"name":"Sleep Medicine: X","volume":"11 ","pages":"Article 100173"},"PeriodicalIF":0.0,"publicationDate":"2026-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146037790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-29DOI: 10.1016/j.sleepx.2025.100172
Reut Gruber , Winfried Randerath
{"title":"Sleep without borders starts here: Principles and pathways for sleep health promotion","authors":"Reut Gruber , Winfried Randerath","doi":"10.1016/j.sleepx.2025.100172","DOIUrl":"10.1016/j.sleepx.2025.100172","url":null,"abstract":"","PeriodicalId":37065,"journal":{"name":"Sleep Medicine: X","volume":"11 ","pages":"Article 100172"},"PeriodicalIF":0.0,"publicationDate":"2025-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146077967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-09DOI: 10.1016/j.sleepx.2025.100171
Galit Levi Dunietz , Erica C. Jansen
{"title":"From awareness to action: Tackling sleep issues in college students","authors":"Galit Levi Dunietz , Erica C. Jansen","doi":"10.1016/j.sleepx.2025.100171","DOIUrl":"10.1016/j.sleepx.2025.100171","url":null,"abstract":"","PeriodicalId":37065,"journal":{"name":"Sleep Medicine: X","volume":"11 ","pages":"Article 100171"},"PeriodicalIF":0.0,"publicationDate":"2025-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145938887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-03DOI: 10.1016/j.sleepx.2025.100166
Merrill S. Wise
{"title":"Promoting pediatric sleep health in low-resource settings: A specialist's perspective","authors":"Merrill S. Wise","doi":"10.1016/j.sleepx.2025.100166","DOIUrl":"10.1016/j.sleepx.2025.100166","url":null,"abstract":"","PeriodicalId":37065,"journal":{"name":"Sleep Medicine: X","volume":"11 ","pages":"Article 100166"},"PeriodicalIF":0.0,"publicationDate":"2025-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145749918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-02DOI: 10.1016/j.sleepx.2025.100168
María Fernanda Gómez Morales , Nicole Cresp Sinning , Carlos H. Schenck
A clinical variant of NREM arousal disorder is described manifesting with predominantly injurious, and exclusively sleep-related scratching without any conscious awareness, and without a history of dermatologic disease. Four patients were clinically evaluated and underwent videopolysomnography (vPSG). Case 1, a 30-year-old woman had a 20-yr history of non-injurious arm scratching/rubbing during sleep. vPSG: forearm rubbing against the chin during N2/N3. Two years later she developed restless bladder symptoms and leg movements before sleep onset. Serum ferritin level: 20.7 Intravenous iron therapy resulted in full control of bedtime leg movements, restless bladder symptoms, and nocturnal scratching. Case 2, a 28-year-old married man had a 1.5-yr history of perianal scratching with excoriations/bleeding during sleep, without other parasomnia. Medical and dermatologic evaluations were negative. vPSG: arousal index of 34/hr, with multiple episodes of perianal scratching. Paroxetine, 20 mg with clonazepam as (0.5–1.0 mg) at bedtime induced 50 % efficacy. Case 3, a 26-year-old African-American female had NREM parasomnias, vigorous sleep-related scratching with keloid formation, and major depression. Medical history was negative. vPSG: arousal index: 28/hr, without abnormal behaviors. Multiple sleep latency test (MSLT): mean sleep latency, 3.6 min, no REM sleep. Idiopathic hypersomnia and NREM parasomnias were diagnosed. Sleep-related scratching and NREM parasomnias responded fully to bedtime clonazepam, 0.5 mg. Case 4, a 50-year-old female had longstanding injurious sleep-related scratching, sleep terrors, and sleep bruxism. vPSG: 55 % sleep efficiency; arousal index: 25/hr, without abnormal behaviors or apneas. MSLT: no objective sleepiness. These cases of sleep-related scratching disorder represent a heterogeneous presumed variant of NREM arousal disorder with various comorbidities, and with full/partial control from diverse therapies.
{"title":"Nocturnal sleep-related scratching disorder as a possible variant of NREM arousal disorder: Clinical features and polysomnographic study of four newly reported cases","authors":"María Fernanda Gómez Morales , Nicole Cresp Sinning , Carlos H. Schenck","doi":"10.1016/j.sleepx.2025.100168","DOIUrl":"10.1016/j.sleepx.2025.100168","url":null,"abstract":"<div><div>A clinical variant of NREM arousal disorder is described manifesting with predominantly injurious, and exclusively sleep-related scratching without any conscious awareness, and without a history of dermatologic disease. Four patients were clinically evaluated and underwent videopolysomnography (vPSG). Case 1, a 30-year-old woman had a 20-yr history of non-injurious arm scratching/rubbing during sleep. vPSG: forearm rubbing against the chin during N2/N3. Two years later she developed restless bladder symptoms and leg movements before sleep onset. Serum ferritin level: 20.7 Intravenous iron therapy resulted in full control of bedtime leg movements, restless bladder symptoms, and nocturnal scratching. Case 2, a 28-year-old married man had a 1.5-yr history of perianal scratching with excoriations/bleeding during sleep, without other parasomnia. Medical and dermatologic evaluations were negative. vPSG: arousal index of 34/hr, with multiple episodes of perianal scratching. Paroxetine, 20 mg with clonazepam as (0.5–1.0 mg) at bedtime induced 50 % efficacy. Case 3, a 26-year-old African-American female had NREM parasomnias, vigorous sleep-related scratching with keloid formation, and major depression. Medical history was negative. vPSG: arousal index: 28/hr, without abnormal behaviors. Multiple sleep latency test (MSLT): mean sleep latency, 3.6 min, no REM sleep. Idiopathic hypersomnia and NREM parasomnias were diagnosed. Sleep-related scratching and NREM parasomnias responded fully to bedtime clonazepam, 0.5 mg. Case 4, a 50-year-old female had longstanding injurious sleep-related scratching, sleep terrors, and sleep bruxism. vPSG: 55 % sleep efficiency; arousal index: 25/hr, without abnormal behaviors or apneas. MSLT: no objective sleepiness. These cases of sleep-related scratching disorder represent a heterogeneous presumed variant of NREM arousal disorder with various comorbidities, and with full/partial control from diverse therapies.</div></div>","PeriodicalId":37065,"journal":{"name":"Sleep Medicine: X","volume":"11 ","pages":"Article 100168"},"PeriodicalIF":0.0,"publicationDate":"2025-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145798229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01DOI: 10.1016/j.sleepx.2025.100167
Júlia Ferrer-Garcia , Maria D. Navarro , Montserrat Abadias , Raquel López-García , Anna Sansalvador , Georgia Gris , Karol Uscamaita
Objective
This exploratory study was designed to assess the effect of a diamine oxidase (DAO) enzyme supplement on insomnia symptoms in patients with alterations of the AOC1 gene, which encodes the DAO enzyme.
Methods
Prospective randomized, double-blind placebo-controlled study. Patients were randomized (1:1:1:1) to 28-day supplementation with the DAO product (12.6 mg/day) or placebo. The Insomnia Severity Index (ISI) and the Pittsburg Sleep Quality Index (PSQI) were completed.
Results
We studied 101 patients (DAO group, n = 50; placebo, n = 51) (73.4 % women, mean age 48.3 years). Decreases in ISI scores were similar in both groups, but severe insomnia at day 28 was higher in the placebo group (5.9 % vs. 2 %). Improvement of PSQI at day 28 was higher in the DAO group (mean [SD] change −1.62 [3.45] vs. −1.47 [3.21]). Improvements of at least 1 point of PSQI in various subscales were higher in the DAO group. Also, in the DAO group and the once-daily regimen, sleep efficiency and use of sleep medication showed significant improvements vs. baseline (mean change of −0.71 [1.43], p = 0.023 and −0.54 [1.14], p = 0.043, respectively). In melatonin users, improvements in ISI at day 7 were higher in the DAO group and persisted until day 28. Overall PSQI and sleep efficiency improved significantly in the DAO group only.
Conclusions
In this exploratory study, the use of a DAO supplement for 28 days improved insomnia symptoms in the presence of genetic variants of the AOC1 gene and showed a synergy with melatonin.
Registered in the ClinicalTrials.gov (NCT07027943).
{"title":"Effect of diamine oxidase (DAO) enzyme dietary supplementation in subjects with insomnia symptoms and single nucleotide polymorphisms of the AOC1 gene: a randomized double-blind placebo-controlled study","authors":"Júlia Ferrer-Garcia , Maria D. Navarro , Montserrat Abadias , Raquel López-García , Anna Sansalvador , Georgia Gris , Karol Uscamaita","doi":"10.1016/j.sleepx.2025.100167","DOIUrl":"10.1016/j.sleepx.2025.100167","url":null,"abstract":"<div><h3>Objective</h3><div>This exploratory study was designed to assess the effect of a diamine oxidase (DAO) enzyme supplement on insomnia symptoms in patients with alterations of the <em>AOC1</em> gene, which encodes the DAO enzyme.</div></div><div><h3>Methods</h3><div>Prospective randomized, double-blind placebo-controlled study. Patients were randomized (1:1:1:1) to 28-day supplementation with the DAO product (12.6 mg/day) or placebo. The Insomnia Severity Index (ISI) and the Pittsburg Sleep Quality Index (PSQI) were completed.</div></div><div><h3>Results</h3><div>We studied 101 patients (DAO group, n = 50; placebo, n = 51) (73.4 % women, mean age 48.3 years). Decreases in ISI scores were similar in both groups, but severe insomnia at day 28 was higher in the placebo group (5.9 % vs. 2 %). Improvement of PSQI at day 28 was higher in the DAO group (mean [SD] change −1.62 [3.45] vs. −1.47 [3.21]). Improvements of at least 1 point of PSQI in various subscales were higher in the DAO group. Also, in the DAO group and the once-daily regimen, sleep efficiency and use of sleep medication showed significant improvements vs. baseline (mean change of −0.71 [1.43], <em>p</em> = 0.023 and −0.54 [1.14], <em>p</em> = 0.043, respectively). In melatonin users, improvements in ISI at day 7 were higher in the DAO group and persisted until day 28. Overall PSQI and sleep efficiency improved significantly in the DAO group only.</div></div><div><h3>Conclusions</h3><div>In this exploratory study, the use of a DAO supplement for 28 days improved insomnia symptoms in the presence of genetic variants of the <em>AOC1</em> gene and showed a synergy with melatonin.</div><div>Registered in the <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> (NCT07027943).</div></div>","PeriodicalId":37065,"journal":{"name":"Sleep Medicine: X","volume":"11 ","pages":"Article 100167"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145665555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-19DOI: 10.1016/j.sleepx.2025.100164
Benedetta Giachetti , Clément Blanloeil , Elena Mugellini , Marco Ghislieri , Dany Jaffuel , Frédéric Gagnadoux , Arnaud Prigent
Rationale
Suboptimal adherence limits the efficacy of Continuous Positive Airway Pressure (CPAP) in Obstructive Sleep Apnea (OSA).
Objective
To determine whether the Monthly Adherence Standard Deviation (MASD), that quantifies the variability in CPAP use during the baseline month (January 2021, at least the fourth month of treatment) provides predictive information about adherence, 6 and 12 months after baseline that would not be captured by the Monthly Adherence Mean (MAM) value alone.
Methods
This retrospective analysis includes CPAP telemonitoring data from a population of 1612 patients. The overall population was randomly assigned to a construction (80 %) and test cohort (20 %) for internal validation. A threshold on baseline MASD was defined using a Receiver Operating Characteristic (ROC) curve.
Results
A MASD threshold of 1.76 h was identified. Based on this threshold and the standard 4 h/day criterion applied to the MAM, patients were classified into four groups: high MAM/low MASD, high MAM/high MASD, low MAM/low MASD, and low MAM/high MASD. Significant differences were observed among the groups 6 and 12 months after baseline data. Six months after baseline, average MAM for each patient group in the test population were 6.84 ± 1.58, 5.66 ± 1.97, 1.27 ± 2.09, and 3.04 ± 1.90 h/day, respectively (p < 0.001); percentages of adherent patients were 91.4 %, 69.9 %, 6.25 %, and 13.9 % (p < 0.001). Similar patterns were found 12 months after baseline.
Conclusions
MASD in CPAP adherence can distinguish between patients with different adherence behaviors 6 and 12 months after, capturing patterns not evident from MAM alone.
{"title":"A new telemonitoring feature for detection of long-term CPAP adherence","authors":"Benedetta Giachetti , Clément Blanloeil , Elena Mugellini , Marco Ghislieri , Dany Jaffuel , Frédéric Gagnadoux , Arnaud Prigent","doi":"10.1016/j.sleepx.2025.100164","DOIUrl":"10.1016/j.sleepx.2025.100164","url":null,"abstract":"<div><h3>Rationale</h3><div>Suboptimal adherence limits the efficacy of Continuous Positive Airway Pressure (CPAP) in Obstructive Sleep Apnea (OSA).</div></div><div><h3>Objective</h3><div>To determine whether the Monthly Adherence Standard Deviation (MASD), that quantifies the variability in CPAP use during the baseline month (January 2021, at least the fourth month of treatment) provides predictive information about adherence, 6 and 12 months after baseline that would not be captured by the Monthly Adherence Mean (MAM) value alone.</div></div><div><h3>Methods</h3><div>This retrospective analysis includes CPAP telemonitoring data from a population of 1612 patients. The overall population was randomly assigned to a construction (80 %) and test cohort (20 %) for internal validation. A threshold on baseline MASD was defined using a Receiver Operating Characteristic (ROC) curve.</div></div><div><h3>Results</h3><div>A MASD threshold of 1.76 h was identified. Based on this threshold and the standard 4 h/day criterion applied to the MAM, patients were classified into four groups: high MAM/low MASD, high MAM/high MASD, low MAM/low MASD, and low MAM/high MASD. Significant differences were observed among the groups 6 and 12 months after baseline data. Six months after baseline, average MAM for each patient group in the test population were 6.84 ± 1.58, 5.66 ± 1.97, 1.27 ± 2.09, and 3.04 ± 1.90 h/day, respectively (<em>p</em> < 0.001); percentages of adherent patients were 91.4 %, 69.9 %, 6.25 %, and 13.9 % (<em>p</em> < 0.001). Similar patterns were found 12 months after baseline.</div></div><div><h3>Conclusions</h3><div>MASD in CPAP adherence can distinguish between patients with different adherence behaviors 6 and 12 months after, capturing patterns not evident from MAM alone.</div></div>","PeriodicalId":37065,"journal":{"name":"Sleep Medicine: X","volume":"10 ","pages":"Article 100164"},"PeriodicalIF":0.0,"publicationDate":"2025-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145614522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-17DOI: 10.1016/j.sleepx.2025.100163
Jonas Bloch Thorlund , Tom Ivar Lund Nilsen , Eivind Schjelderup Skarpsno
Objective
Insomnia is common among individuals with chronic musculoskeletal pain, and both conditions have been linked to mortality. However, the joint association of chronic multisite pain and insomnia with all-cause mortality is unknown, which we aimed to investigate in this study.
Methods
We used data from 39,545 persons participating in the third wave of the Norwegian HUNT Study (2006–08) with complete information on both musculoskeletal pain and insomnia symptoms, linked to the national Cause of Death Registry. Hazard ratios (HRs) with 95 % confidence intervals (CIs) were calculated to assess the risk of death associated with the joint association of insomnia and chronic multisite pain.
Results
Compared to individuals without chronic musculoskeletal pain and no insomnia, individuals with multisite chronic pain had a HR for all-cause mortality of 1.21 (95 % CI 1.01 to 1.43) if they reported insomnia and a HR of 1.00 (0.91–1.11) if they did not suffer from insomnia. Compared to the same reference category, pain-free individuals with insomnia had a HR of 1.05 (95 % 0.83 to 1.34). Our data showed no evidence of a synergistic effect between chronic multisite pain and insomnia on all-cause mortality.
Conclusion
Individuals with chronic multisite pain and insomnia appeared to have higher all-cause mortality compared to pain-free persons without insomnia. Although speculative, these findings suggest that improving sleep quality in individuals with chronic multisite pain and insomnia may contribute to better overall health and potentially lower the risk of death from all causes.
失眠在慢性肌肉骨骼疼痛患者中很常见，这两种情况都与死亡率有关。然而，慢性多部位疼痛和失眠与全因死亡率的联合关系尚不清楚，我们在本研究中旨在调查这一点。方法：我们使用了参与挪威HUNT研究第三期（2006-08）的39,545人的数据，包括肌肉骨骼疼痛和失眠症状的完整信息，并与国家死亡原因登记相关联。计算95%置信区间（ci）的风险比（hr），以评估与失眠和慢性多部位疼痛联合相关的死亡风险。结果与没有慢性肌肉骨骼疼痛和没有失眠的个体相比，患有多部位慢性疼痛的个体报告失眠的全因死亡率为1.21 (95% CI 1.01至1.43)，如果他们没有失眠，则HR为1.00（0.91-1.11）。与同一参考类别相比，无痛失眠患者的风险比为1.05（95% 0.83至1.34）。我们的数据显示，没有证据表明慢性多部位疼痛和失眠对全因死亡率有协同作用。结论慢性多部位疼痛伴失眠症患者的全因死亡率明显高于无疼痛伴失眠症患者。尽管是推测性的，但这些发现表明，改善慢性多部位疼痛和失眠患者的睡眠质量可能有助于改善整体健康状况，并可能降低各种原因导致的死亡风险。
{"title":"Increased mortality in people with chronic multisite pain and insomnia: the HUNT study","authors":"Jonas Bloch Thorlund , Tom Ivar Lund Nilsen , Eivind Schjelderup Skarpsno","doi":"10.1016/j.sleepx.2025.100163","DOIUrl":"10.1016/j.sleepx.2025.100163","url":null,"abstract":"<div><h3>Objective</h3><div>Insomnia is common among individuals with chronic musculoskeletal pain, and both conditions have been linked to mortality. However, the joint association of chronic multisite pain and insomnia with all-cause mortality is unknown, which we aimed to investigate in this study.</div></div><div><h3>Methods</h3><div>We used data from 39,545 persons participating in the third wave of the Norwegian HUNT Study (2006–08) with complete information on both musculoskeletal pain and insomnia symptoms, linked to the national Cause of Death Registry. Hazard ratios (HRs) with 95 % confidence intervals (CIs) were calculated to assess the risk of death associated with the joint association of insomnia and chronic multisite pain.</div></div><div><h3>Results</h3><div>Compared to individuals without chronic musculoskeletal pain and no insomnia, individuals with multisite chronic pain had a HR for all-cause mortality of 1.21 (95 % CI 1.01 to 1.43) if they reported insomnia and a HR of 1.00 (0.91–1.11) if they did not suffer from insomnia. Compared to the same reference category, pain-free individuals with insomnia had a HR of 1.05 (95 % 0.83 to 1.34). Our data showed no evidence of a synergistic effect between chronic multisite pain and insomnia on all-cause mortality.</div></div><div><h3>Conclusion</h3><div>Individuals with chronic multisite pain and insomnia appeared to have higher all-cause mortality compared to pain-free persons without insomnia. Although speculative, these findings suggest that improving sleep quality in individuals with chronic multisite pain and insomnia may contribute to better overall health and potentially lower the risk of death from all causes.</div></div>","PeriodicalId":37065,"journal":{"name":"Sleep Medicine: X","volume":"10 ","pages":"Article 100163"},"PeriodicalIF":0.0,"publicationDate":"2025-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145568761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号